Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report of the Company for the financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Johnson Pharmacare Ltd (BSE: 532154) submitted its 31st Annual Report for FY 2024-25 along with the notice of its AGM scheduled for 25th September 2025 at 3:00 PM via video conferencing. The company reported a net loss of Rs. 58.38 lakh for the year, with no revenue generated from operations and no significant business activity carried out during the period. No dividend was recommended due to the loss. The paid-up share capital stands at Rs. 55 crore (55 crore equity shares of Rs. 1 each). Shareholders will vote on re-appointing M/s Rishi Sekhri and Associates as statutory auditors for a 5-year term till 2030, and on two special resolutions seeking approval to raise borrowing limits and make investments/loans/guarantees up to Rs. 100 crore each. The Secretarial Auditor flagged multiple compliance lapses, including non-publication of board meeting and results notices, no internal auditor, no company secretary, delayed ROC filings, and non-maintenance of the Structured Digital Database.
For shareholders, this is a routine regulatory filing but the underlying financials are weak — the company is operationally inactive, running at a loss, and has several unresolved compliance issues. The proposed Rs. 100 crore borrowing and investment limits could be significant if the company activates any business plans, but for now there is no revenue activity to support such moves.